Review The roles of the kynurenine pathway in COVID-19 neuropathogenesis 2024 Dehhaghi et al

Discussion in 'Long Covid research' started by Andy, May 29, 2024.

  1. Andy

    Andy Committee Member

    Messages:
    22,391
    Location:
    Hampshire, UK
    Abstract

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the highly contagious respiratory disease Corona Virus Disease 2019 (COVID-19) that may lead to various neurological and psychological disorders that can be acute, lasting days to weeks or months and possibly longer. The latter is known as long-COVID or more recently post-acute sequelae of COVID (PASC). During acute COVID-19 infection, a strong inflammatory response, known as the cytokine storm, occurs in some patients. The levels of interferon‐γ (IFN‐γ), interferon-β (IFN-β), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) are particularly increased. These cytokines are known to activate the enzyme indoleamine 2,3-dioxygenase 1 (IDO-1), catalysing the first step of tryptophan (Trp) catabolism through the kynurenine pathway (KP) leading to the production of several neurotoxic and immunosuppressive metabolites. There is already data showing elevation in KP metabolites both acutely and in PASC, especially regarding cognitive impairment. Thus, it is likely that KP involvement is significant in SARS-CoV-2 pathogenesis especially neurologically.

    Open access, https://link.springer.com/article/10.1007/s15010-024-02293-y
     
  2. Creekside

    Creekside Senior Member (Voting Rights)

    Messages:
    1,064
    While I appreciate the parts that support my theory for ME (that QUIN is at least partly responsible for cognitive symptoms), the study seems like vague speculation. It's based on findings from other studies, but we all know how reliable that sort of data is, since such studies often have contradictory findings. I suppose its main value is a vote for more research into the KP in ME.
     

Share This Page